Search

Your search keyword '"Umutlu L"' showing total 550 results
Start Over Author "Umutlu L"
550 results on '"Umutlu L"'

1. MRI-guided active surveillance in patients with ISUP 1 prostate cancer – A multi-institutional validation of the discrimination of the PRECISE Score

Author

Sushentsev, N., primary, Wiesenfarth, M., additional, Dixius, M., additional, Kastner, C., additional, Borkowetz, A., additional, Platzek, I., additional, Thomas, C., additional, Kesch, C., additional, Umutlu, L., additional, Reis, H., additional, Rau, T., additional, Lenders, L., additional, Spahn, M., additional, Boschheidgen, M., additional, Antoch, G., additional, Albers, P., additional, Barrett, T., additional, Schimmöller, L., additional, Hadaschik, B., additional, and Radtke, J.P., additional

Published
2024
Full Text
View/download PDF

4. MRI-guided active surveillance in patients with ISUP 1 prostate cancer - a multi-institutional validation of the discrimination of the PRECISE score

Author

Radtke, JP, Sushentsev, N, Wiesenfarth, M, Dixius, M, Kastner, C, Borkowetz, A, Thomas, C, Platzke, I, Kesch, C, Umutlu, L, Reis, H, Rau, T, Lenders, L, Spahn, M, Boschheidgen, M, Antoch, G, Barrett, T, Schimmöller, L, Hadaschik, B, Radtke, JP, Sushentsev, N, Wiesenfarth, M, Dixius, M, Kastner, C, Borkowetz, A, Thomas, C, Platzke, I, Kesch, C, Umutlu, L, Reis, H, Rau, T, Lenders, L, Spahn, M, Boschheidgen, M, Antoch, G, Barrett, T, Schimmöller, L, and Hadaschik, B

Published
2024

7. DGN-Handlungsempfehlung (S1-Leitlinie) – PSMA-Liganden-PET/CT in der Diagnostik des Prostatakarzinoms – Stand: 01/2022 – AWMF-Registernummer: 031-055

Author

Afshar-Oromieh, A., Eiber, M., Fendler, W., Schmidt, M., Rahbar, K., Ahmadzadehfar, H., Umutlu, L., Hadaschik, B., Hakenberg, O., Fornara, P., Kurth, J., Neels, O., Wester, H.-J., Schwaiger, M., Kopka, K., Haberkorn, U., Herrmann, K., and Krause, B.

Subjects
Prostate Specific Membrane Antigen, PET/CT, Prostate Cancer, PSMA, Medizin, Radiology, Nuclear Medicine and imaging, General Medicine, Guideline, Positron Emission Tomography
Abstract

PSMA-PET/CT for imaging prostate cancer (PC) has spread worldwide since its clinical introduction in 2011. The majority of experiences have been collected for PSMA-PET-imaging of recurrent PC. Data for primary staging of high-risk PC are highly promising. Meanwhile, a plethora of PSMA-ligands are available for clinical use (e.g. 68Ga-PSMA-11, 68GaPSMA-I&T, 68Ga-PSMA-617, 18F-DCFBC, 18F-DCFPyL, 18F-PSMA-1007, 18F-rhPSMA-7 and 18F-JK-PSMA-7). However, an official approval is available only for 68Ga-PSMA-11 (approved by the US FDA in 2020) and 18F-DCFPyL (approved by the US FDA in 2021). Recommendations for acquisition times vary from 1-2h p.i. It has been shown that for the majority of tumour lesions, the contrast in PSMAPET/CT increases with time. Therefore, additional late imaging can help to clarify unclear findings. PSMA-PET/CT should be performed prior to commencing an androgen deprivation therapy (ADT) since (long term) ADT reduces the visibility of PC lesions. Following injection of PSMA-ligands, hydration and forced diuresis are recommended for PSMA-ligands with primarily excretion via the kidneys in order to increase the visibility of tumour lesions adjacent to the urinary bladder. PSMA-ligands are physiologically taken up in multiple normal organs. For some 18F-labelled PSMA-ligands, presence of unspecific focal bone uptake has been reported. When using these tracers, focal bone uptake without CT-correlate should be interpreted with great caution. Besides prostate cancer, practically all solid tumors express PSMA in their neovasculature thereby taking up PSMA-ligands, although usually at a lower extent compared to PC. Also multiple benign lesions and inflammatory processes (e.g. lymph nodes) take up PSMA-ligands, also usually at lower extent compared to PC.

Published
2023

16. First Clinical Experience with Gallium-68-OPS-202 PET for Imaging SCLC

Author

Kersting, D., additional, Sandach, P., additional, Sraieb, M., additional, Wiesweg, M., additional, Metzenmacher, M., additional, Darwiche, K., additional, Oezkan, F., additional, Bölükbas, S., additional, Stuschke, M., additional, Umutlu, L., additional, Fendler, W. P., additional, Wienker, J., additional, Eberhardt, W., additional, Schuler, M., additional, Herrmann, K., additional, and Hautzel, H., additional

Published
2023
Full Text
View/download PDF

18. 99P Fibroblast activation protein alpha (FAP) as theranostic target in solitary fibrous tumor

Author

Hamacher, R.W., primary, Pabst, K.M., additional, Cheung, P.F., additional, Heilig, C.E., additional, Hüllein, J., additional, Liffers, S-T., additional, Schaarschmidt, B.M., additional, Costa, P., additional, Kessler, L., additional, Falkenhorst, J., additional, Glimm, H., additional, Umutlu, L., additional, Schuler, M.H.H., additional, Hübschmann, D., additional, Bauer, S., additional, Fröhling, S., additional, Herrmann, K., additional, Siveke, J., additional, Schildhaus, H-U., additional, and Fendler, W., additional

Published
2023
Full Text
View/download PDF

19. EP04.02-007 First Comprehensive Lung Cancer Long-Term Survivorship Program- Competing Risks

Author

Nadjm, S., primary, Exner, J.-P.H., additional, Hepp De Los Rios, R., additional, Metzenmacher, M., additional, Hoffmann, A.-C., additional, Gauler, T., additional, Aigner, C., additional, Stamatis, G., additional, Oezkan, F., additional, Schulte, C., additional, Darwiche, K., additional, Taube, C., additional, Theegarten, D., additional, Plönes, T., additional, Pöttgen, C., additional, Umutlu, L., additional, Hautzel, H., additional, Schuler, M., additional, Stuschke, M., additional, and Eberhardt, W.E.E., additional

Published
2022
Full Text
View/download PDF

20. EP04.02-005 First Comprehensive Lung Cancer Long-Term Survivorship Program - Late Toxicities and Overall Survival

Author

Exner, J.-P.H., primary, Nadjm, S., additional, Hepp de los Rios, R., additional, Metzenmacher, M., additional, Hoffmann, A.-C., additional, Gauler, T.C., additional, Aigner, C., additional, Stamatis, G., additional, Oezkan, F., additional, Schulte, C., additional, Darwiche, K., additional, Taube, C., additional, Theegarten, D., additional, Plönes, T., additional, Poettgen, C., additional, Umutlu, L., additional, Hautzel, H., additional, Schuler, M., additional, Stuschke, M., additional, and Eberhardt, W.E.E., additional

Published
2022
Full Text
View/download PDF

21. EP04.01-016 First Comprehensive Lung Cancer Long-Term Survivorship Analysis - Late Toxicities and Overall Survival

Author

Exner, J.-P., primary, Nadjm, S., additional, Hepp de los Rios, R., additional, Metzenmacher, M., additional, Hoffmann, A.-C., additional, Gauler, T.C., additional, Aigner, C., additional, Stamatis, G., additional, Oezkan, F., additional, Schulte, C., additional, Darwiche, K., additional, Taube, C., additional, Theegarten, D., additional, Plönes, T., additional, Pöttgen, C., additional, Umutlu, L., additional, Hautzel, H., additional, Schuler, M., additional, Stuschke, M., additional, and Eberhardt, W.E.E., additional

Published
2022
Full Text
View/download PDF

23. Combined PET/MRI: from Status Quo to Status Go. Summary Report of the Fifth International Workshop on PET/MR Imaging; February 15–19, 2016; Tübingen, Germany

Author

Bailey, D. L., Pichler, B. J., Gückel, B., Barthel, H., Beer, A. J., Botnar, R., Gillies, R., Goh, V., Gotthardt, M., Hicks, R. J., Lanzenberger, R., la Fougere, C., Lentschig, M., Nekolla, S. G., Niederdraenk, T., Nikolaou, K., Nuyts, J., Olego, D., Riklund, K. Åhlström, Signore, A., Schäfers, M., Sossi, V., Suminski, M., Veit-Haibach, P., Umutlu, L., Wissmeyer, M., and Beyer, T.

Published
2016
Full Text
View/download PDF

29. Klinische Entscheidungshilfe für das axilläre Lymphknoten-Staging bei neu diagnostizierten Brustkrebspatientinnen auf der Grundlage von 18F-FDG PET/MRI und maschinellem Lernen

Author

Morawitz, S J, additional, Sigl, B, additional, Rubbert, C, additional, Bruckmann, M N, additional, Dietzel, F, additional, Baltzer, P, additional, Herrmann, K, additional, Umutlu, L, additional, Antoch, G, additional, Caspers, J, additional, and Kirchner, J, additional

Published
2022
Full Text
View/download PDF

33. Multiparametric 18F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.

Author

Umutlu, L, Kirchner, J, Bruckmann, N-M, Morawitz, J, Antoch, G, Ting, S, Bittner, A-K, Hoffmann, O, Häberle, L, Ruckhäberle, E, Catalano, OA, Chodyla, M, Grueneisen, J, Quick, HH, Fendler, WP, Rischpler, C, Herrmann, K, Gibbs, P, Pinker, K, Umutlu, L, Kirchner, J, Bruckmann, N-M, Morawitz, J, Antoch, G, Ting, S, Bittner, A-K, Hoffmann, O, Häberle, L, Ruckhäberle, E, Catalano, OA, Chodyla, M, Grueneisen, J, Quick, HH, Fendler, WP, Rischpler, C, Herrmann, K, Gibbs, P, and Pinker, K

Abstract

BACKGROUND: The aim of this study was to assess whether multiparametric 18F-FDG PET/MRI-based radiomics analysis is able to predict pathological complete response in breast cancer patients and hence potentially enhance pretherapeutic patient stratification. METHODS: A total of 73 female patients (mean age 49 years; range 27-77 years) with newly diagnosed, therapy-naive breast cancer underwent simultaneous 18F-FDG PET/MRI and were included in this retrospective study. All PET/MRI datasets were imported to dedicated software (ITK-SNAP v. 3.6.0) for lesion annotation using a semi-automated method. Pretreatment biopsy specimens were used to determine tumor histology, tumor and nuclear grades, and immunohistochemical status. Histopathological results from surgical tumor specimens were used as the reference standard to distinguish between complete pathological response (pCR) and noncomplete pathological response. An elastic net was employed to select the most important radiomic features prior to model development. Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were calculated for each model. RESULTS: The best results in terms of AUCs and NPV for predicting complete pathological response in the entire cohort were obtained by the combination of all MR sequences and PET (0.8 and 79.5%, respectively), and no significant differences from the other models were observed. In further subgroup analyses, combining all MR and PET data, the best AUC (0.94) for predicting complete pathologic response was obtained in the HR+/HER2- group. No difference between results with/without the inclusion of PET characteristics was observed in the TN/HER2+ group, each leading to an AUC of 0.92 for all MR and all MR + PET datasets. CONCLUSION: 18F-FDG PET/MRI enables comprehensive high-quality radiomics analysis for the prediction of pCR in breast cancer patients, especially in those with HR+/HER2- receptor status.

Published
2022

34. Ultraschnelle PET Bildgebung durch die Kombination aus digitaler PET/CT und Nachrekonstruktion durch Künstliche Intelligenz

Author

Kersting, D., additional, Hosch, R., additional, Weber, M., additional, Sraieb, M., additional, Flaschel, N., additional, Haubold, J., additional, Kim, M., additional, Umutlu, L., additional, Kleesiek, J., additional, Herrmann, K., additional, Nensa, F., additional, Rischpler, C., additional, Koitka, S., additional, and Seifert, R., additional

Published
2022
Full Text
View/download PDF

36. Artificial intelligence for the differentiation between multiple sclerosis and glioma II° or III° using 18F-FET-PET imaging

Author

Rauschenbach, L, Kebir, S, Weber, M, Lazaridis, L, Schmidt, T, Keyvani, K, Schäfer, N, Umutlu, L, Pierscianek, D, Stuschke, M, Forsting, M, Sure, U, Kleinschnitz, C, Antoch, G, Colletti, P, Rubello, D, Herrmann, K, Herrlinger, U, Scheffler, B, Bundschuh, R, and Glas, M

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Objective: To evaluate the diagnostic significance of 18F-FET-PET imaging for the differentiation between multiple sclerosis (MS) and World Health Organization (WHO) grade 2/3 glioma (glioma II°/III°). Methods: We retrospectively screened for patients in whom 18F-FET-PET imaging[for full text, please go to the a.m. URL], 72. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Polnischen Gesellschaft für Neurochirurgie

Published
2021
Full Text
View/download PDF

40. Detection of significant prostate cancer using target saturation in transperineal magnetic resonance imaging/transrectal ultrasonography–fusion biopsy: A prospective, randomized comparison to conventional target biopsy

Author

Saner, Y., primary, Wiesenfarth, M., additional, Tschirdewahn, S., additional, Püllen, L., additional, Bonekamp, D., additional, Krafft, U., additional, Kesch, C., additional, Darr, C., additional, Forsting, M., additional, Umutlu, L., additional, Hadaschik, B.A., additional, and Radtke, J.P., additional

Published
2021
Full Text
View/download PDF

41. Multiparametric Integrated 18F-FDG PET/MRI-Based Radiomics for Breast Cancer Phenotyping and Tumor Decoding.

Author

Umutlu, L, Kirchner, J, Bruckmann, NM, Morawitz, J, Antoch, G, Ingenwerth, M, Bittner, A-K, Hoffmann, O, Haubold, J, Grueneisen, J, Quick, HH, Rischpler, C, Herrmann, K, Gibbs, P, Pinker-Domenig, K, Umutlu, L, Kirchner, J, Bruckmann, NM, Morawitz, J, Antoch, G, Ingenwerth, M, Bittner, A-K, Hoffmann, O, Haubold, J, Grueneisen, J, Quick, HH, Rischpler, C, Herrmann, K, Gibbs, P, and Pinker-Domenig, K

Abstract

BACKGROUND: This study investigated the performance of simultaneous 18F-FDG PET/MRI of the breast as a platform for comprehensive radiomics analysis for breast cancer subtype analysis, hormone receptor status, proliferation rate and lymphonodular and distant metastatic spread. METHODS: One hundred and twenty-four patients underwent simultaneous 18F-FDG PET/MRI. Breast tumors were segmented and radiomic features were extracted utilizing CERR software following the IBSI guidelines. LASSO regression was employed to select the most important radiomics features prior to model development. Five-fold cross validation was then utilized alongside support vector machines, resulting in predictive models for various combinations of imaging data series. RESULTS: The highest AUC and accuracy for differentiation between luminal A and B was achieved by all MR sequences (AUC 0.98; accuracy 97.3). The best results in AUC for prediction of hormone receptor status and proliferation rate were found based on all MR and PET data (ER AUC 0.87, PR AUC 0.88, Ki-67 AUC 0.997). PET provided the best determination of grading (AUC 0.71), while all MR and PET analyses yielded the best results for lymphonodular and distant metastatic spread (0.81 and 0.99, respectively). CONCLUSION: 18F-FDG PET/MRI enables comprehensive high-quality radiomics analysis for breast cancer phenotyping and tumor decoding, utilizing the perks of simultaneously acquired morphologic, functional and metabolic data.

Published
2021

44. A comparison of detectability and image quality in Iodine-124 PET across different PET system generations to optimize the protocol for recurrent thyroid cancer patients

Author

Kersting, D, additional, Jentzen, W, additional, Sraieb, M, additional, Fragoso Costa, P, additional, Conti, M, additional, Umutlu, L, additional, Antoch, G, additional, Nader, M, additional, Herrmann, K, additional, Fendler, WP, additional, Rischpler, C, additional, and Weber, M, additional

Published
2021
Full Text
View/download PDF

46. Detektion lokoregionärer Lymphknotenmetastasen bei Patientinnen mit neu diagnostiziertem Mammakarzinom in der Zeit des PET/MRT

Author

Morawitz, J, additional, Bruckmann, N, additional, Dietzel, F, additional, Ullrich, T, additional, Bittner, A, additional, Mohrmann, S, additional, Häberle, L, additional, Ingenwerth, M, additional, Sawicki, L, additional, Umutlu, L, additional, Herrmann, K, additional, Antoch, G, additional, and Kirchner, J, additional

Published
2021
Full Text
View/download PDF

48. Ga-68-PSMA-11 PET/CT improves tumor detection and impacts management in patients with hepatocellular carcinoma (HCC)

Author

Hirmas, N, additional, Leyh, C, additional, Sraieb, M, additional, Barbato, F, additional, Schaarschmidt, BM, additional, Umutlu, L, additional, Nader, M, additional, Wedemeyer, H, additional, Ferdinandus, J, additional, Rischpler, C, additional, Herrmann, K, additional, Costa, PF, additional, Lange, CM, additional, Weber, MM, additional, and Fendler, WP, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results